# Metabolic Dysfunction-associated Steatohepatitis (MASH) affects an estimated 250 million people globally.

*biotech · news · 2026-05-19 · FinanzNachrichten*

## Key points

- ESSENCE trial data confirm semaglutide's favorable hepatic safety profile in MASH patients, regardless of characteristics.
- First dedicated data for Japanese and menopausal women show semaglutide's liver benefits extend across diverse populations.
- ESSENCE Menopause subgroup analysis provides targeted evidence for a group historically excluded from liver trials.
- Real-world data reveal significant quality-of-life impairment, cost, and underdiagnosis in MASH, highlighted at EASL 2026.

**Companies:** Novo Nordisk
**Countries:** Denmark, Japan, Spain, United Kingdom, Germany

[Read the full story on FinanzNachrichten](https://www.finanznachrichten.de/nachrichten-2026-05/68535971-novo-nordisk-a-s-novo-nordisk-to-unveil-data-showing-semaglutide-tackles-the-liver-disease-crisis-affecting-about-1-in-3-people-living-with-overweigh-399.htm)

---

Canonical: https://newsio.io/n/ee6a3574-a088-4ca0-8739-727678735311/metabolic-dysfunction-associated-steatohepatitis-mash-affects-an-estimated-250-m
Summarized by Newsio from FinanzNachrichten. https://newsio.io/how-it-works